Signatera Surges in Liquid Biopsy Race with New Lung Cancer Data and a Japan Approval

On Tuesday, Natera announced its Signatera test was approved by Japan’s Pharmaceuticals and Medical Devices Agency as a companion diagnostic in muscle-invasive bladder cancer to guide adjuvant atezolizumab (Tecentriq) treatment. The post Si…

Summary from Inside Precision Medicine.

Coverage 1 article · 1 outlet

1. Inside Precision Medicine yesterday
   Signatera Surges in Liquid Biopsy Race with New Lung Cancer Data and a Japan Approval ↗